Nathan D. Schley

Discovery of G2019S Mutant Selective LRRK2 Inhibitors Based on an Indazole Octahydrocyclopenta[ c ]pyrrole-Based Hybrid Chemotype

Abstract LRRK2 is an important kinase target for Parkinson’s disease with disease-modifying potential. In this article, we report our efforts to identify indazole octahydrocyclopenta[c]pyrrole-based hybrid chemotypes as LRRK2 inhibitors utilizing a structure-guided hybridization...